Scalper1 News
Specialty drugmaker Mallinckrodt (MNK) announced a $2.3 billion deal Thursday to acquire privately held Ikaria, which was greeted with enthusiasm on the stock market. Ikaria makes INOmax, an inhaled nitric oxide used to treat newborns with respiratory problems. Mallinckrodt said the deal will expand its hospital business, adding $150 million and 25 cents a share to its 2015 financials. “This product has been growing sales slow and steady in the Scalper1 News
Scalper1 News